Paradigm Biopharmaceuticals Ltd
ASX:PAR
Income Statement
Earnings Waterfall
Paradigm Biopharmaceuticals Ltd
Income Statement
Paradigm Biopharmaceuticals Ltd
| Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
2
N/A
|
3
+51%
|
3
+0%
|
3
+18%
|
4
+25%
|
5
+15%
|
4
-12%
|
9
+111%
|
8
-1%
|
8
-7%
|
9
+13%
|
8
-5%
|
8
-10%
|
6
-15%
|
7
+3%
|
7
+7%
|
|
| Gross Profit | |||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
8
N/A
|
8
-2%
|
8
-7%
|
9
+14%
|
8
-4%
|
8
-10%
|
6
-15%
|
7
+3%
|
7
+7%
|
|
| Operating Income | |||||||||||||||||
| Operating Expenses |
(7)
|
(9)
|
(10)
|
(12)
|
(20)
|
(17)
|
(32)
|
(43)
|
(50)
|
(48)
|
(53)
|
(60)
|
(77)
|
(65)
|
(21)
|
(23)
|
|
| Selling, General & Administrative |
(2)
|
(2)
|
(3)
|
(4)
|
(4)
|
(4)
|
(6)
|
(10)
|
(10)
|
(9)
|
(10)
|
(7)
|
(6)
|
(7)
|
(5)
|
(6)
|
|
| Research & Development |
(5)
|
(7)
|
(7)
|
(8)
|
(9)
|
(13)
|
(26)
|
(34)
|
(40)
|
(39)
|
(43)
|
(53)
|
(71)
|
(58)
|
(16)
|
(18)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
(7)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(5)
N/A
|
(6)
-23%
|
(7)
-13%
|
(9)
-24%
|
(16)
-88%
|
(12)
+25%
|
(28)
-127%
|
(35)
-24%
|
(41)
-20%
|
(40)
+3%
|
(44)
-10%
|
(52)
-17%
|
(70)
-35%
|
(59)
+16%
|
(15)
+75%
|
(16)
-11%
|
|
| Pre-Tax Income | |||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
1
|
1
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
(7)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
|
| Pre-Tax Income |
(5)
N/A
|
(6)
-23%
|
(7)
-13%
|
(16)
-123%
|
(16)
-5%
|
(12)
+25%
|
(28)
-127%
|
(34)
-23%
|
(41)
-18%
|
(39)
+3%
|
(44)
-12%
|
(52)
-18%
|
(70)
-35%
|
(59)
+16%
|
(15)
+75%
|
(19)
-28%
|
|
| Net Income | |||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(5)
|
(6)
|
(7)
|
(16)
|
(16)
|
(12)
|
(28)
|
(34)
|
(41)
|
(39)
|
(44)
|
(52)
|
(70)
|
(59)
|
(15)
|
(19)
|
|
| Net Income (Common) |
(5)
N/A
|
(6)
-23%
|
(7)
-13%
|
(16)
-123%
|
(16)
-5%
|
(12)
+25%
|
(28)
-127%
|
(34)
-23%
|
(41)
-18%
|
(39)
+3%
|
(44)
-12%
|
(52)
-18%
|
(70)
-35%
|
(59)
+16%
|
(15)
+75%
|
(19)
-28%
|
|
| EPS (Diluted) |
-0.04
N/A
|
-0.05
-25%
|
-0.05
N/A
|
-0.11
-120%
|
-0.08
+27%
|
-0.06
+25%
|
-0.12
-100%
|
-0.16
-33%
|
-0.19
-19%
|
-0.16
+16%
|
-0.17
-6%
|
-0.18
-6%
|
-0.23
-28%
|
-0.17
+26%
|
-0.04
+76%
|
-0.05
-25%
|
|